Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identification of invasive fungal diseases in immunocompromised patients by combining an Aspergillus specific PCR with a multifungal DNA-microarray from primary clinical samples.
Boch T, Reinwald M, Postina P, Cornely OA, Vehreschild JJ, Heußel CP, Heinz WJ, Hoenigl M, Eigl S, Lehrnbecher T, Hahn J, Claus B, Lauten M, Egerer G, Müller MC, Will S, Merker N, Hofmann WK, Buchheidt D, Spiess B. Boch T, et al. Among authors: lauten m. Mycoses. 2015 Dec;58(12):735-45. doi: 10.1111/myc.12424. Epub 2015 Oct 26. Mycoses. 2015. PMID: 26497302
[Azole resistance in Aspergillus fumigatus - epidemiology and detection in immunocompromised patients in Germany].
Buchheidt D, Spiess B, Cornely OA, Vehreschild MJ, Hamprecht A, Rath PM, Steinmann J, Groß U, Bader O, Lauten M, Reinwald M, Hofmann WK. Buchheidt D, et al. Among authors: lauten m. Dtsch Med Wochenschr. 2014 Jun;139(25-26):1373-6. doi: 10.1055/s-0034-1370130. Epub 2014 Jun 10. Dtsch Med Wochenschr. 2014. PMID: 24914515 Review. German. No abstract available.
Incidence of Cyp51 A key mutations in Aspergillus fumigatus-a study on primary clinical samples of immunocompromised patients in the period of 1995-2013.
Spiess B, Postina P, Reinwald M, Cornely OA, Hamprecht A, Hoenigl M, Lass-Flörl C, Rath PM, Steinmann J, Miethke T, Lauten M, Will S, Merker N, Hofmann WK, Buchheidt D. Spiess B, et al. Among authors: lauten m. PLoS One. 2014 Jul 29;9(7):e103113. doi: 10.1371/journal.pone.0103113. eCollection 2014. PLoS One. 2014. PMID: 25072733 Free PMC article.
Invasive Mold Infection of the Central Nervous System in Immunocompromised Children.
Porto L, You SJ, Attarbaschi A, Cario G, Döring M, Moser O, Mücke U, Poyer F, Temme C, Voigt S, Groll AH, Lauten M, Hattingen E, Lehrnbecher T. Porto L, et al. Among authors: lauten m. J Fungi (Basel). 2020 Oct 16;6(4):226. doi: 10.3390/jof6040226. J Fungi (Basel). 2020. PMID: 33081142 Free PMC article.
Antimicrobial use in pediatric oncology and hematology in Germany and Austria, 2020/2021: a cross-sectional, multi-center point-prevalence study with a multi-step qualitative adjudication process.
Papan C, Reifenrath K, Last K, Attarbaschi A, Graf N, Groll AH, Hübner J, Laws HJ, Lehrnbecher T, Liese JG, Martin L, Tenenbaum T, Vieth S, von Both U, Wagenpfeil G, Weichert S, Hufnagel M, Simon A; AB-PPS PedOnc Study Group. Papan C, et al. Lancet Reg Health Eur. 2023 Mar 1;28:100599. doi: 10.1016/j.lanepe.2023.100599. eCollection 2023 May. Lancet Reg Health Eur. 2023. PMID: 37180743 Free PMC article.
Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia.
Lauten M, Möricke A, Beier R, Zimmermann M, Stanulla M, Meissner B, Odenwald E, Attarbaschi A, Niemeyer C, Niggli F, Riehm H, Schrappe M. Lauten M, et al. Haematologica. 2012 Jul;97(7):1048-56. doi: 10.3324/haematol.2011.047613. Epub 2012 Jan 22. Haematologica. 2012. PMID: 22271901 Free PMC article. Clinical Trial.
60 results